Dr Mahkam Zanganeh, Robert Duggan and Manmeet Soni will join board of directors alongside Chaim Hurvitz
Cancer biopharma company Genoscience Pharma, has appointed four new members to its board of directors. Dr Mahkam Zanganeh, Robert Duggan and Manmeet Soni, respectively the former chief operating officer, chief executive officer and chief financial officer of Pharmacyclics, are joining the board along with Chaim Hurvitz, who has worked in many management roles for Teva International Group. Their arrival is accompanied by an increase in capital, the terms of which have not been disclosed. While at Pharmacyclics Pharmaceuticals, in less than seven years, Mahkam Zanganeh and Robert Duggan developed and brought to the market Imbruvica, a treatment for Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) and Waldenstrom's macroglobulinemia (WM).
